[go: up one dir, main page]

MX2017011633A - Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas. - Google Patents

Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.

Info

Publication number
MX2017011633A
MX2017011633A MX2017011633A MX2017011633A MX2017011633A MX 2017011633 A MX2017011633 A MX 2017011633A MX 2017011633 A MX2017011633 A MX 2017011633A MX 2017011633 A MX2017011633 A MX 2017011633A MX 2017011633 A MX2017011633 A MX 2017011633A
Authority
MX
Mexico
Prior art keywords
tumor
lung cancer
small cell
cell lung
reduce
Prior art date
Application number
MX2017011633A
Other languages
English (en)
Inventor
Lander Cynthia
Brophy Colleen
Peterson Caryn
Luber Andrew
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of MX2017011633A publication Critical patent/MX2017011633A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)

Abstract

La invención descrita proporciona composiciones farmacéuticas, sistemas y métodos para tratar un tumor sólido de cáncer de pulmón de células no pequeñas (NSCLC) que comprende una población de células tumorales. El método incluye administrarle una composición farmacéutica que comprende una cantidad terapéutica de un polipéptido que tiene la secuencia de aminoácidos YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) o un equivalente funcional de este, y un portador farmacéuticamente aceptable, en donde la cantidad terapéutica del polipéptido es eficaz para inhibir una actividad cinasa en la población de células tumorales y para reducir la proliferación de las células cancerosas, para reducir el tamaño del tumor, para reducir la carga tumoral, para inducir la muerte de las células tumorales, para superar la quimiorresistencia tumoral, para mejorar la quimiosensibilidad tumoral, o una combinación de estos.
MX2017011633A 2015-03-12 2016-03-10 Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas. MX2017011633A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132374P 2015-03-12 2015-03-12
PCT/US2016/021843 WO2016145234A2 (en) 2015-03-12 2016-03-10 Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same

Publications (1)

Publication Number Publication Date
MX2017011633A true MX2017011633A (es) 2017-11-02

Family

ID=56880599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011633A MX2017011633A (es) 2015-03-12 2016-03-10 Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.

Country Status (13)

Country Link
US (1) US9999655B2 (es)
EP (1) EP3268022A4 (es)
JP (1) JP2018512401A (es)
KR (1) KR20170125090A (es)
CN (1) CN107921082A (es)
AU (1) AU2016229017A1 (es)
BR (1) BR112017019343A2 (es)
CA (1) CA2978941A1 (es)
HK (1) HK1249433A1 (es)
MX (1) MX2017011633A (es)
RU (1) RU2017135072A (es)
SG (1) SG11201707281QA (es)
WO (1) WO2016145234A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102827A1 (en) * 2016-12-04 2018-06-07 Expression Pathology, Inc. Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
WO2018216009A1 (en) * 2017-05-22 2018-11-29 The National Institute For Biotechnology In The Negev Ltd. Ben-Gurion University Of The Negev Biomarkers for diagnosis of lung cancer
US10952799B2 (en) * 2017-05-31 2021-03-23 Covidien Lp Systems and methods for navigational bronchoscopy and selective drug delivery
US20190134153A1 (en) * 2017-06-12 2019-05-09 Moerae Matrix, Inc. Immunomodulatory effect of inhaled kinase inhibitor peptides in lung
JP2021527642A (ja) * 2018-06-12 2021-10-14 ユニヴェルシテ ド ジュネーヴＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｇｅｎｅｖｅ ペプチドプロテインキナーゼｃ阻害剤及びその使用
WO2020102670A1 (en) * 2018-11-15 2020-05-22 Nantomics, Llc Classification based on characterization analysis methods and systems
WO2021019526A1 (en) 2019-07-29 2021-02-04 Yeda Research And Development Co. Ltd. Methods of treating and diagnosing lung cancer
CN113261532A (zh) * 2020-02-17 2021-08-17 中山大学 一种肺癌动物模型的构建方法
WO2021178449A1 (en) * 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
CN116437962A (zh) * 2020-11-18 2023-07-14 隆萨本德公司 包括血管生成抑制剂的可吸入干粉调配物
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
KR20250094717A (ko) * 2022-10-27 2025-06-25 브리스톨-마이어스 스큅 컴퍼니 Mk2 억제제 및 그의 용도

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
FI79651C (fi) 1982-10-08 1990-02-12 Glaxo Group Ltd Doseringsanordning foer medicin.
FR2585563B1 (fr) 1985-07-30 1993-11-12 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
CA2118513A1 (en) 1992-04-24 1993-11-11 David A. Zarling In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CA2178729A1 (en) 1993-12-09 1995-06-15 Eric B. Kmiec Compounds and methods for site-directed mutations in eukaryotic cells
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
EP1165050B1 (en) 1999-04-05 2006-03-29 Mannkind Corporation Methods for fine powder formation
EP2280020B1 (en) 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20060039985A1 (en) 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP1791542B1 (en) 2004-08-23 2015-05-20 Mannkind Corporation Diketopiperazine salts for drug delivery
BRPI0514410A (pt) 2004-08-23 2008-06-10 Mannkind Corp fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
KR101643478B1 (ko) 2005-09-14 2016-07-27 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
CA2643464C (en) 2006-02-22 2018-09-04 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
DK2349310T3 (da) 2008-10-20 2014-08-11 Moerae Matrix Inc Polypeptid til behandling eller forebyggelse af adhæsioner
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20110288036A1 (en) 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure
US10105356B2 (en) * 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
JP6031510B2 (ja) * 2011-04-12 2016-11-24 モイライ マトリックス インコーポレイテッド 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法
WO2013182912A2 (en) 2012-06-06 2013-12-12 Fundacio Privada Institut De Recerca Biomedica Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US20140072613A1 (en) 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring

Also Published As

Publication number Publication date
SG11201707281QA (en) 2017-10-30
WO2016145234A3 (en) 2016-11-03
HK1249433A1 (zh) 2018-11-02
EP3268022A4 (en) 2018-11-21
AU2016229017A1 (en) 2017-09-28
BR112017019343A2 (pt) 2018-05-02
CA2978941A1 (en) 2016-09-15
US20160263187A1 (en) 2016-09-15
WO2016145234A2 (en) 2016-09-15
KR20170125090A (ko) 2017-11-13
US9999655B2 (en) 2018-06-19
RU2017135072A (ru) 2019-04-10
JP2018512401A (ja) 2018-05-17
RU2017135072A3 (es) 2019-09-30
CN107921082A (zh) 2018-04-17
EP3268022A2 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
MX2017011633A (es) Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
ECSP18087352A (es) Formulaciones de un inhibidor de lsd1
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
EA201791576A1 (ru) Ингибитор jak
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
MX383484B (es) Método para tratar el cáncer.
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
CL2019003407A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
BR112016028641A2 (pt) ?método para tratar câncer?
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112017025698A2 (pt) composições e métodos para inibir a expressão do gene de hif2alfa
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
AR099068A1 (es) Anticuerpo anti-netrina-1
BR112017018198A2 (pt) inibição da atividade de olig2
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.